Oncology Chromosome Analysis - Hematologic Cancer

Clinical Use

Use

Oncology Chromosome Analysis - Hematologic Cancer is employed to detect chromosomal changes such as translocations, large duplications, deletions, and inversions within neoplastic cells specific to certain hematologic cancers such as leukemias. This test is crucial for diagnosing disorders characterized by dysfunctions in repair versus apoptotic pathway regulation and for identifying prognostic anomalies in patients already diagnosed. It is also utilized in monitoring the treatment response of hematologic cancers, providing valuable insights in clinical settings.

Special Instructions

Specimens must be handled with care to ensure viability. Bone marrow and leukemic blood samples should arrive within 48 hours of collection at ambient temperatures. Detailed instructions should be followed for sample collection to guarantee successful analysis.

Limitations

The standard cytogenetic methodology employed does not routinely identify subtle rearrangements smaller than 5Mb and is unable to detect microdeletions or microduplications easily diagnosed via Fluorescent In-Situ Hybridization. It is important to note that the results do not rule out potential genetic conditions that may remain undetected through cytogenetic analysis, necessitating the consideration of other testing if clinically indicated.

Test Details